Publications by authors named "J Antonio Virizuela"
Article Synopsis
- The PROpel study showed that combining olaparib with abiraterone significantly improves progression-free survival in patients with metastatic castration-resistant prostate cancer (mCRPC), regardless of genetic mutation status.
- This report presents safety analyses, revealing that olaparib plus abiraterone has notable adverse effects when compared to placebo plus abiraterone, particularly concerning anemia, nausea, and fatigue.
- The most severe side effects occurred early in treatment, and a higher percentage of patients discontinued due to adverse events, especially anemia, when taking the olaparib combination.
Background: Preclinical and early clinical data suggest that the irreversible ErbB family blocker afatinib may be effective in urothelial cancers harbouring ERBB mutations.
Methods: This open-label, phase II, single-arm trial (LUX-Bladder 1, NCT02780687) assessed the efficacy and safety of second-line afatinib 40 mg/d in patients with metastatic urothelial carcinoma with ERBB1-3 alterations. The primary endpoint was 6-month progression-free survival rate (PFS6) (cohort A); other endpoints included ORR, PFS, OS, DCR and safety (cohorts A and B).
Introduction: Cancer patients often suffer from malnutrition and early detection and raising awareness of nutritional issues is crucial in this population.
Methods: The Spanish Oncology Society (SEOM) conducted the Quasar_SEOM study to investigate the current impact of the Anorexia-Cachexia Syndrome (ACS). The study employed questionnaires and the Delphi method to gather input from both cancer patients and oncologists on key issues related to early detection and treatment of ACS.
Immune checkpoint inhibitors (ICI) have changed the prognosis of many tumors. However, concerning associated cardiotoxicity has been reported. Little is known about the real-life incidence-specific surveillance protocols or the translational correlation between the underlying mechanisms and the clinical presentation of ICI-induced cardiotoxicity.
View Article and Find Full Text PDFQuality of life with palbociclib plus fulvestrant placebo plus fulvestrant in postmenopausal women with endocrine-sensitive hormone receptor-positive and HER2-negative advanced breast cancer: patient-reported outcomes from the FLIPPER trial.
Ther Adv Med Oncol
January 2023
Background: In the FLIPPER trial, palbociclib/fulvestrant significantly improved progression-free survival (PFS) compared with placebo/fulvestrant in postmenopausal women with HR+/HER2- advanced breast cancer (ABC).
Objective: We assessed health-related quality of life (QoL) using patient-reported outcomes (PROs).
Design And Methods: In this phase II double-blinded study, PROs were assessed at baseline after every three cycles and at the end of the treatment using the European Organisation for Research and Treatment of Cancer QLQ-C30 and QLQ-BR23.